LEADER 01135nam--2200385---450 
001 990005905190203316
005 20240213133617.0
010   $a978-0-12-405880-4
035   $a000590519
035   $aUSA01000590519
035   $a(ALEPH)000590519USA01
035   $a000590519
100   $a20131105d2013----km-y0itay50------ba
101   $aeng
102   $aGB
105   $a||||||||001yy
200 1 $aAntiviral agents$fedited by Erik De Clercq$gserial editor, S.J. Enna$gmanaging editor, Lynn LeCourt
210   $aElsevier$cAmsterdam [etc.]$d2013
215   $aXIV, 369 p.$d23 cm
225 2 $aAdvances in pharmacology$v67
410  0$1001000609420$12001$aAdvances in pharmacology$v67
606   $aFarmacologia$2BNCF
606 0 $aChemioterapici$2BNCF
676   $a616.0194
702  1$aDE CLERCQ,$bErik
702  1$aENNA,$bS.J.
702  1$aLECOURT,$bLynN
801  0$aIT$bsalbc$gISBD
912   $a990005905190203316
951   $a615 AIP/67$b5694 FARM$c615$d00344258
959   $aBK
969   $aFAR
979   $aCHIARA$b90$c20131105$lUSA01$h1446
996   $aAntiviral agents$91074831
997   $aUNISA